HHS’s 340B drug discount program is set to shift to a rebate model on New Year’s Day. But a lawsuit and temporary restraining order filed by the AHA and others may block the change from going live on time.
The nylon loop on some devices can fail to release while removing polyps. Because of the severe risk to patient health, the FDA has designated this recall a Class I.
Artera, a company that utilizes AI for patient communications, made the announcement while revealing it has achieved $100 million in annual revenue. Its products use AI for follow-ups after patient care, in addition to supporting clinical decisions.
The sensor-guided device delivers continuous hemodynamic measurements and rapid left ventricular pacing during TAVR procedures. Back in 2023, it was at the heart of a $253 million acquisition.
When fillers are injected without imaging guidance, there is a risk that the materials could be misplaced. A common complication of this scenario is vascular occlusion, which occurs when filler is injected in a way that disrupts bloodflow to arteries.
Hemostemix believes its new cell therapy platform can help treat peripheral artery disease, congestive heart failure, cardiomyopathy and other serious medical conditions. The company plans on scooping up multiple practices to conduct additional research and increase the use of its platform.
American football isn’t the only contact sport that has medical experts concerned with the brain health of athletes. New evidence suggests certain soccer players may be at heightened risk of long-term brain abnormalities, too.
Daniel West, MD, is suing Trinity Health Muskegon and seeking whistleblower protection after reporting alleged malpractice and being summarily terminated.
HHS’s 340B drug discount program is set to shift to a rebate model on New Year’s Day. But a lawsuit and temporary restraining order filed by the AHA and others may block the change from going live on time.
The nylon loop on some devices can fail to release while removing polyps. Because of the severe risk to patient health, the FDA has designated this recall a Class I.
Artera, a company that utilizes AI for patient communications, made the announcement while revealing it has achieved $100 million in annual revenue. Its products use AI for follow-ups after patient care, in addition to supporting clinical decisions.
